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Abstract
The use of microtubule stabilizing agents (MSA) is a promising strategy for anti-cancer therapy alone
and as part of combined treatment modalities with ionizing radiation. However MSA-provoked
molecular and cellular processes including the regulation of intercellular, paracrine signaling pathways
are far from clear. Here we investigated the interference of the novel, clinically relevant MSA
patupilone (epothilone B) with the tumor-cell derived vascular endothelial growth factor (VEGF), which
is most relevant for tumor angiogenesis. Low-dose, sub-nanomolar concentrations of patupilone
specifically reduced hypoxia-driven stabilization of the transcription factor HIF-1α in the
patupilone-sensitive lung adenocarcinoma cell line A549, but not in the mutant derivative cell line
A549.EpoB40. Patupilone further reduced hypoxia-induced VEGF expression and secretion but only in
the A549 wildtype cell line. In the wildtype cell line, ionizing radiation alone induced
hypoxia-dependent VEGF-expression but a strong dominant counteracting effect of patupilone was
always observed when ionizing radiation was combined with patupilone, on the level of HIF-1α protein
stability, VEGF-expression and VEGF-secretion. These results demonstrate that patupilone and ionizing
radiation dysregulate hypoxia-induced stress responses, which might contribute to the potency of this
promising, combined treatment modality.
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Summary 
The use of microtubule stabilizing agents (MSA) is a promising strategy for anti-cancer therapy alone 
and as part of combined treatment modalities with ionizing radiation. However MSA-provoked 
molecular and cellular processes including the regulation of intercellular, paracrine signaling pathways 
are far from clear. Here we investigated the interference of the novel, clinically relevant MSA 
patupilone (epothilone B) with the tumor-cell derived vascular endothelial growth factor (VEGF), 
which is most relevant for tumor angiogenesis. Low-dose, sub-nanomolar concentrations of patupilone 
specifically reduced hypoxia-driven stabilization of the transcription factor HIF-1α in the patupilone-
sensitive lung adenocarcinoma cell line A549, but not in the mutant derivative cell line A549.EpoB40. 
Patupilone further reduced hypoxia-induced VEGF expression and secretion but only in the A549 
wildtype cell line. In the wildtype cell line, ionizing radiation alone induced hypoxia-dependent 
VEGF-expression but a strong dominant counteracting effect of patupilone was always observed when 
ionizing radiation was combined with patupilone, on the level of HIF-1α  protein stability, VEGF-
expression and VEGF-secretion. These results demonstrate that patupilone and ionizing radiation 
dysregulate hypoxia-induced stress responses, which might contribute to the potency of this 
promising, combined treatment modality.  
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1. Introduction 
Interference with microtubule function leads to defective mitotic spindle formation, cell cycle arrest in 
M-phase, and eventually to apoptosis or post-mitotic cell death. The use of microtubule interfering 
agents is therefore a promising strategy for anti-cancer therapy alone and as part of combined 
treatment modalities with cytotoxic agents [1]. The effects of microtubule interfering agents at the 
biochemical level are well investigated, but additional cytotoxic effects due to signaling interference 
have been identified, which merit further investigation [2-5]. 
We previously investigated the combined treatment modality of ionizing radiation (IR) with the novel, 
clinically relevant microtubule stabilizing agent patupilone (Epothilone B), and interestingly, the 
combination of patupilone with IR resulted in vitro only in an additive cytotoxic effect (against 
various cancer cell types) but in a supra-additive tumor growth delay against tumor xenografts derived 
from the same tumor cells [2, 4]. The accumulation of tumor cells in the most radiosensitive G2-M 
phase of the cell cycle represents the major rationale for the sensitization to IR [6-9], though other S-
phase progression-related mechanisms have been observed as well [4]. Additional anti-vascular and 
anti-angiogenic effects might contribute to the supra-additive tumor growth delay observed in vivo, 
and indeed, direct targeting of endothelial cells [10-12] and indirect, anti-angiogenic interference with 
the secretion of pro-angiogenic factors from tumor cells have been proposed [2, 13]. Microtubule 
stabilizing and destabilizing agents block the nuclear translocation and correct assembly of the 
hypoxia inducible factor (HIF) by disrupting the structural organization of the microtubule 
cytoskeleton. In consequence, the downstream signaling of HIF-1 target genes in response to hypoxia 
is compromised [2-3, 5]. A reduction of pro-angiogenic (and cytoprotective) cytokine secretion by 
patupilone via inhibition of HIF could contribute to this mechanism [14-15]. However, such a link 
between microtubule-interfering agents and HIF-signaling has only been investigated at high-dose 
concentrations of these agents.  
The group of microtubule stabilizing agents (MSA) are amongst the most promising chemotherapeutic 
agents for the treatment of non-small cell lung cancer. The MSA docetaxel is the only 
chemotherapeutic agent currently approved for first- and second-line treatment of advanced non-small 
cell lung cancer. Although single agent docetaxel as well as combined treatments with platinum-based 
agents have led to significant progress in the treatment of lung cancer, its use often results in strong 
side-effects [16-18]. In order to overcome such limitations, new MSA with fewer side-effects, superior 
pharmacological and anticancer activity are under investigation in order to maximize the induced 
benefits for lung cancer patients. At the same time and based on the immense technological 
improvements of current radiotherapy with regard to treatment conformality and accuracy 
radiotherapy is becoming standard of care for the management of lung cancer. As such, combined 
radiochemotherapy treatment modalities are also of high interest for this tumor entity. 
Here we investigated the treatment response of low-dose, sub-nanomolar concentrations of patupilone 
alone and in combination with IR specifically on hypoxia-driven VEGF expression and secretion in 
  
the patupilone-sensitive lung adenocarcinoma cell line A549 and the mutant derivative A549.EpoB40, 
which is strongly resistant to patupilone due to a genetically defined β-tubulin-mutation [3, 19-21]. 
Thereby we aim to further explore the interference of patupilone with the tumor-cell derived growth 
factor most relevant for tumor angiogenesis.  
 
2. Materials and methods 
2.1 Drugs and cell lines 
Patupilone (epothilone B, EPO906) was provided by Novartis Pharma AG (Basel, Switzerland). The 
human cell line pair A549 and A549.EpoB40 was obtained from the laboratory of Dr. SB Horwitz. 
2.2 Cell cultures, drug preparation and irradiation 
The human non-small cell lung cancer lines A549 and A549.EpoB40 were grown in RPMI 1640 
containing 10% (v/v) fetal bovine serum, 1% (v/v) penicillin-streptomycin and 1% (v/v) L-glutamine 
at 37ºC in 5% CO2. A549.EpoB40 is derived from A549 by stepwise selection with patupilone and 
contains a point mutation in class 1 β-tubulin (β292 from Gln to Glu) which is associated with a ~95-
fold resistance to patupilone [20]. The A549.EpoB40 cell line was grown and maintained in medium 
containing 10 nM patupilone. For in vitro experiments, patupilone was dissolved in DMSO (1 mM 
stock solution) and further diluted with media containing 10% FCS.  
Irradiation of cell cultures was carried out using a Gulmay 200 kV X-ray unit at 100 cGy/min at room 
temperature. For combined treatment and hypoxia experiments, cells were pretreated with patupilone 
24 hours before applying hypoxia or hypoxia mimicking conditions. Cells were irradiated 4 hours 
thereafter. 
2.3 Cultivation of cells under hypoxia 
Hypoxia experiments with A549 and A549.EpoB40 were performed for various time spans at 0.2% or 
1% oxygen using a Invivo2 400 hypoxia workstation (Biotrace International). Cells were preincubated 
with patupilone for 24 hours under normoxic conditions, followed by incubation in the hypoxia 
chamber or under hypoxia-mimicking conditions, using Dimethyloxaloylglycine (DMOG) (Biomol 
GmbH, Hamburg, Germany), a prolyl-4-hydroxylase inhibitor (0.25 and 1 mM, respectively) [2]. 
2.4 Western blot analysis  
A549 and A549.EpoB40 were cultivated in 6-well dishes, washed twice with ice cold PBS, and whole 
cell extracts were obtained by scraping cells with 150 μl of pre-cooled hypotonic lysis buffer 
(Laemmli-buffer (4% SDS, 15% glycerol, 0.125 M Tris HCl) and 2xSDS-buffer (20% glycerol, 0.100 
M Tris, 0.1% bromphenol blue; 10% β-mercaptoethanol) 1:1) and immediately heated for 5 minutes at 
95˚C on a heating block. Hypoxic probes were retrieved under hypoxic conditions. Proteins were 
resolved by 10% SDS-PAGE, followed by western blotting onto polyvinylidene difluoride 
membranes. Membranes were probed with the HIF-1α antibody (HIF-1α (H-206), Santa Cruz 
Biotecnology, Inc.). Antibody detection was achieved by enhanced chemoluminescence (Amersham, 
  
Piscataway, NJ) according to the protocol of the manufacturer. All experiments were carried out 
independently at least thrice. 
2.5 Isolation and analysis of RNA 
Total RNA was isolated using the Quiagen RNeasy Plus Mini Kit (Qiagen, Hombrechtikon, 
Switzerland). First-strand cDNA synthesis was performed with 1–5 mg total RNA using reverse 
transcriptase enzyme, and mRNA levels were measured by real-time quantitative PCR using a 
SybrGreen qPCR reagent kit (Applied Biosystems) in combination with a 7900 HT TaqMan rtPCR 
system (Applied Biosystems) and SDS manager 2.3, patch 3-software. Real-time PCR was carried out 
as recommended by the manufacturer. To verify equal input levels, β-actin was used as a 
housekeeping gene and the data were expressed as ratios relative to β-actin levels. The primers 
(Microsynth, Balgach, Switzerland) used for RT-PCR of VEGF-A mRNA were as follows: (a) 
forward primer, 5'-ATG AAC TTT CTG CTG TCT TGG GT-3’and (b) reverse primer: 5'-TCA CCG 
CCT CGG CTT GTC AC-3’).[22] The forward primer sequence for β-actin mRNA (internal control) 
quantification was 5'-GTC CTC TCC CAA GTC CTC ACA-3'; the reverse primer sequence was 5'-
AAT TTA CAC GAA AGC AAT CCT ATC AC-3'. 
2.6 ELISA 
Supernatants of cultured cells were centrifuged at 10’000 g to remove debris and stored at -80˚C. Cell 
numbers were manually counted after trypsination to allow correction to cell number. Total protein 
content of supernatant was measured with a Nanodrop spectrophotometer (Witec AG, Switzerland) at 
an absorbance of 280 nm. The concentration of VEGF-levels in the supernatant was determined using 
the commercially available Quantikine® Human VEGF Immunoassay kit (R&D Systems GmbH, 
Wiesbaden-Nordenstadt, Germany), following the manufacturer’s description. 
2.7 Statistical analysis 
Experiments presented in the figures are representative of three or more different repetitions if not 
otherwise indicated. Statistical analysis was performed using GraphPad Prism5 software (GraphPad 
Software Inc.). Student’s t-test was used to evaluate the differences between normoxic and hypoxic 
and between drug and IR treated samples. The level of significance was set at 0.05. 
 
3. Results 
3.1 Stabilization of microtubules leads to inhibition of the HIF pathway 
The hypoxia-stabilized HIF-1α-subunit of the transcription factor HIF represents a major determinant 
for hypoxia-regulated expression of pro-angiogenic growth factors. To determine hypoxia-dependent 
HIF-1α stabilization on patupilone treatment, patupilone-sensitive lung adenocarcinoma A549 
wildtype and patupilone-resistant A549.EpoB40 cells were pretreated for 24 hours with increasing 
concentrations of  patupilone (0-1 nM) followed by incubation in 0.2% pO2 or addition of the hypoxia-
mimicking agent DMOG (0.25 and 1 mM, respectively). Maximum stabilization of the HIF-1α subunit 
under hypoxic conditions was observed at 4 hours of hypoxic exposure and in hypoxia-mimicking 
  
conditions (Fig. 1) and was reduced again to background levels at the 24 hour time point in both cell 
lines (data not shown). In the A549 wildtype cells HIF-1α stabilization was abrogated by patupilone in 
a dose-dependent way, while HIF-1α protein levels were not reduced in the A549.EpoB40 cells on 
patupilone treatment (Fig. 1). HIF-1α stabilization in the A549.EpoB40 cells was only affected at 
approximately 100-fold higher concentrations of patupilone, which correlates to the 100-fold-reduced 
affinity of mutant β-tubulin to patupilone in these cells (data not shown).  
We previously observed an at least additive reduction of microvessel density in tumor xenografts 
derived from A549-adenocarcinoma tumor cells on combined treatment with patupilone and IR [2]. 
This might be due to a combined effect on the HIF-1α -dependent expression or secretion of pro-
angiogenic factors such as the vascular endothelial growth factor (VEGF). Irradiation of cells alone 
did not affect HIF-1α-level but synergized with patupilone. When A549 wildtype cells were pretreated 
with low dose patupilone (0.2 nM and 0.5 nM; with only a minor effect on HIF-1α stability alone), 
followed by incubation with DMOG and irradiation 2 hours thereafter,  HIF-1α-protein levels were 
even further reduced than after treatment with patupilone alone. No downregulation of HIF-1α was 
observed in the β-tubulin-mutated counterpart cells after treatment with either condition (Fig. 2).  
3.2 Downstream signaling of HIF at the level of VEGF mRNA is affected by treatment with patupilone  
To determine the consequence of deregulated HIF-1α stability on the expression of the major pro-
angiogenic factor VEGF, VEGF mRNA levels were quantified by real-time PCR. Incubation of cells 
for 24 h under hypoxic (0.2% pO2) or hypoxia mimicking conditions (DMOG) resulted in a 6- and 4-
fold upregulation of VEGF mRNA levels, in A549 wildtype and A549EpoB40 mutated lung 
adenocarcinoma cells, respectively (Fig. 3). Similar to the effect on HIF-1α -stability, pretreatment 
with patupilone (0.5 nM) resulted in diminished VEGF mRNA upregulation in the A549 cells by 43% 
(p=0.002), but not in the patupilone-resistant A549.EpoB40 cells, when treated under hypoxic or 
hypoxia mimicking conditions. 
Under hypoxia-mimicking conditions irradiation alone (4 hours after start of DMOG-treatment) 
resulted in enhanced VEGF expression in the A549 wildtype cells but not in the A549EpoB40 cells, 
which are more radiation resistant [2]. The discrepancy between IR-downregulated HIF-1α-levels (see 
above) and IR-enhanced VEGF-mRNA levels might be due to the different time points of data 
collection. However and more important, the relative downregulation of VEGF mRNA levels in 
patupilone-pretreated cells was observed to a similar extent in irradiated as in unirradiated A549 
wildtype cells (reduction by 45% of initial values (p=0.006), while patupilone treatment did not 
downregulate VEGF expression in irradiated A549.EpoB40 cells.  
3.3 VEGF protein secretion with drug pretreatment is inhibited in A549  
To determine the amount of secreted VEGF in response to treatment with IR and patupilone, cells 
were preincubated with patupilone for 24 hours, incubated under hypoxia mimicking conditions (for 
30 hours) and irradiated at the 4 hour time point following DMOG-addition. Supernatants were 
  
collected during a 12 hour interval of incubation under hypoxia-mimicking conditions (18 h-30 h time 
period) and were analyzed for VEGF protein levels by ELISA.  
As expected from the real time PCR results, secreted VEGF levels in supernatants derived from 
DMOG-treated cells were 3-4-fold enhanced in both A549 wildtype and A549.EpoB40 mutated cells 
in comparison to supernatants derived from cells kept in normoxia. Of note, while irradiation 
enhanced VEGF mRNA levels in A549 cells kept under hypoxia-mimicking conditions (see above), 
no further increased VEGF protein level could be detected in supernatants derived from these cells. 
Interestingly, in response to patupilone treatment (0.5 nM) a significant reduction in VEGF-secretion 
under normoxic (31%, p=0.008) as well as DMOG conditions (34%, p<0.001) was determined in the 
patupilone-sensitive cell line A549 (Fig. 4) but not in the patupilone-resistant cell line. Similar results 
were determined when cells were kept under hypoxia (1%) instead of DMOG-treatment or in 
supernatants collected over a 48 hour-interval from cells treated under the same conditions (data not 
shown). Of note, prior results demonstrated that the anti-proliferative effect of patupilone under 
normoxic and hypoxic (pO2 of 1%) conditions remains the same (data not shown [2]). Thus combined 
treatment modality of low doses of patupilone in combination with ionizing radiation also bears 
promise against tumors with an increased hypoxic fraction. 
Overall our results demonstrate that low-dose treatment of tumor cells with patupilone antagonizes a 
major pro-angiogenic signaling axis on the level of the hypoxia-inducible factor HIF-1α, thereby 
reducing hypoxia-enhanced expression and subsequent secretion of the vascular endothelial growth 
factor VEGF. 
 
4. Discussion 
Here, we investigated the regulation of the hypoxia-inducible factor HIF-1α and its downstream target 
VEGF by the novel, clinically relevant microtubule stabilizing agent patupilone alone and in 
combination with ionizing radiation. The effect of patupilone was specifically tested in the lung 
adenocarcinoma cell line A549 at subnanomolar concentrations, which do not induce the classic MSA-
dependent M-phase arrest and have only minimal cytotoxic activity. Under hypoxia HIF-1α-protein 
levels were reduced by low-dose treatment with patupilone. Subsequently VEGF mRNA transcription 
was diminished, and reduced levels of secreted VEGF-protein were detected in cell supernatants. 
Furthermore patupilone repressed IR-induced VEGF mRNA expression. The specificity of patupilone 
and the involvement of the microtubular system were evidenced by the lack of a treatment response in 
the mutated A549 cell line derivative harboring a specific β-tubulin mutation, which abrogates 
patupilone-binding.  
A variety of microtubule targeting drugs has previously been described to exhibit anti-HIF properties 
in tumor cells exposed to hypoxia [3, 5]. 2-Methoxyestradiol and classic microtubule stabilizing 
(taxanes) and microtubule destabilizing (vincristine, discodermolide) agents downregulated HIF-1α at 
the posttranscriptional level resulting in reduced HIF-1α protein synthesis and subsequent reduced 
  
nuclear accumulation and transcriptional activity. Microtubule stabilizing agents may interfere with a 
regulated HIF-1α mRNA-microtubule association and guided nuclear import of the HIF-1α subunit 
into the nucleus [3, 5]. However these experiments were performed at concentrations of the respective 
compounds that strongly induced microtubule stabilization and destabilization, respectively and 
treatment-dependent cell cycle redistribution into G2-M phase. Here we demonstrate that low-dose 
concentrations of patupilone (epothilone B) strongly reduce HIF-1α protein levels and subsequent 
downregulation of the major downstream target VEGF at up to 100-fold lower concentrations, which 
do not result in microtubule interference-related G2-M cell cycle redistribution, and that patupilone 
counteracts a potential pro-angiogenic stress response [23]. Furthermore these low concentrations of 
patupilone are still β-tubulin-specific, without any effect in the A549-mutated cell line and are 
sufficient to sensitize for ionizing radiation ([2, 4], and data not shown).  
Despite direct in vitro cytotoxicity against endothelial cells [11], our prior results allocate part of the 
anti-angiogenic effect of patupilone to interference with the tumor cellular stress response. In vitro 
experiments performed with a hypoxia-regulated reporter gene assay demonstrated that patupilone 
reduces the expression of the HIF-1 “transcriptome” but only in patupilone sensitive tumor cells, 
thereby abrogating the paracrine, tumor cell-mediated protection of the tumor endothelium [2]. Here 
we specifically determine downregulation of VEGF expression and subsequent secretion of the HIF-
1α downstream target and major endothelial growth and survival factor VEGF on cellular treatment 
with patupilone. Similar to patupilone in this study, the MSA paclitaxel also downregulates VEGF-
gene expression and VEGF-protein secretion, however only at high cytotoxic doses of paclitaxel as 
demonstrated in MKN45 and HT29 gastrointestinal carcinoma cell lines ( ≥ 0.1 μM) [24-25].  
Regulation of HIF-1α in response to irradiation is complex and dependent on multiple factors 
including hypoxia and reoxygenation-enhanced generation of reactive oxygen species [14-15]. 
Furthermore the treatment response in vitro might not reflect the in vivo situation with its dynamic 
adaptation to microenvironmental changes in response to radiotherapy. Here we determined multiple 
endpoints in response to IR alone and in combination with patupilone in the two related 
adenocarcinoma cell lines, (HIF-1α protein levels, VEGF expression and secretion). In part they are 
difficult to be reconciled. For example IR enhanced VEGF expression under hypoxic condition, but no 
enhanced HIF-1α protein levels could be detected in irradiated cells. This might be due to undetected 
posttranslational modifications, which increases the transcriptional activity of HIF-1α, but might also 
be due to incomplete analysis of HIF-1α due to technical limitations. In this study, patupilone-reduced 
VEGF-mRNA expression was normalized to β-actin-housekeeping gene expression and is therefore 
not affected by a small reduction of cell viability at patupilone-concentrations used (20% at 0.5 nM, 
data not shown). However we can not exclude that patupilone-reduced VEGF-secretion might in part 
derive from patupilone-affected cell viability at a later time point. On the other hand MSA may also 
interfere with the secretion of vesicles and proteases required for VEGF-release along a dynamic 
microtubular system [26], which is currently investigated as part of ongoing studies. 
  
However and more important a strong dominant counteracting effect was always observed when IR 
was combined with patupilone, on the level of HIF-1 protein stability, VEGF-expression and VEGF-
secretion.  
Overall, we demonstrate that low dose, subnanomolar treatment of lung carcinoma cells with the 
clinically relevant microtubule stabilizing agent patupilone interferes with the major hypoxic signaling 
axes. This effect is most probably linked to microtubules interference, as indicated by the negative 
results in the β-tubulin-mutated drug-resistant A549.EpoB40 cell line. Patupilone treatment results in 
reduced VEGF expression and secretion under hypoxic conditions and subsequent lack of paracrine 
protection of the tumor vasculature. Thus besides its direct cytotoxic and radiosensitizing effect on the 
tumor cell level, patupilone might concomitantly render endothelial cells more vulnerable to ionizing 
radiation. This eventually contributes to the strong supra-additive treatment response observed in vivo 
in response to the combined treatment modality of IR with patupilone [2, 4] and will also be of future 
clinical interest [27]. Thus a pharmacological approach which interferes with the hypoxic signaling of 
neoplastic cells renders these cells more radiosensitive and subsequently enhances the tumor response 
to ionizing radiation. 
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Figure legends 
Fig. 1. Patupilone reduces HIF-1α levels under hypoxia. A) A549 wildtype and B) A549.EpoB40 cells 
were treated for 24 hours with increasing concentrations of patupilone and then subjected to hypoxia 
or hypoxia mimicking conditions (0.2% pO2 or DMOG, respectively), for additional 4 hours. HIF-1α 
protein levels were determined by western blotting. Band intensities of two independent experiments 
were quantified, pooled and are plotted. 
 
Fig. 2. Enhanced reduction of HIF-1α levels on combined treatment with patupilone and ionizing 
radiation: A549 wildtype and A549.EpoB40 cells were treated for 24 hours with increasing 
concentrations of patupilone, subjected to hypoxia mimicking conditions, irradiated after 2 hours and 
analyzed for HIF-1a protein levels 4 hours after start of DMOG incubation. Band intensities of three 
independent experiments were quantified, pooled and are plotted: columns: mean; bars: ± SE. 
 
Fig. 3. Regulation of hypoxia-driven VEGF-mRNA-expression by patupilone and IR. A) A549 
wildtype and A549.EpoB40 cells were treated for 24 hours with patupilone (0.5 nM) and subjected to 
hypoxia or hypoxia mimicking conditions (0.2% pO2 or DMOG, respectively) for 24 hours. B) A549 
wildtype and A549.EpoB40 cells were treated for 24 hours with patupilone (0.5 nM), subjected to 
hypoxia mimicking conditions and irradiated after 4 hours. VEGF mRNA was determined 24 hours 
after start of DMOG incubation by real time PCR and normalized to β-action mRNA expression. Data 
were pooled from three independent experiments, columns: mean; bars: ± SE. 
 
Fig. 4. Regulation of hypoxia-driven VEGF-secretion by patupilone and IR. A549 wildtype and 
A549.EpoB40 cells were treated for 24 hours with patupilone (0.5 nM), subjected to hypoxia 
mimicking conditions for 30 hours A) and irradiated at the 4 hour time point following DMOG-
addition B). Supernatants were collected during a 12 hour interval of incubation under hypoxia-
mimicking conditions (18 h-30 h time period) and analyzed for VEGF protein levels by ELISA. Data 
presented are derived from three independent experiments, columns: mean; bars: ± SE. 
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